ME02447B - Spoj indola i njegova farmaceutska upotreba - Google Patents

Spoj indola i njegova farmaceutska upotreba

Info

Publication number
ME02447B
ME02447B MEP-2016-107A MEP10716A ME02447B ME 02447 B ME02447 B ME 02447B ME P10716 A MEP10716 A ME P10716A ME 02447 B ME02447 B ME 02447B
Authority
ME
Montenegro
Prior art keywords
groups
group
optionally substituted
alkoxy
substituents
Prior art date
Application number
MEP-2016-107A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Teruhiko Inoue
Tetsudo Kaya
Shinichi Kikuchi
Koji Matsumura
Ritsuki Masuo
Motoya Suzuki
Michihide Maekawa
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of ME02447B publication Critical patent/ME02447B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MEP-2016-107A 2009-11-25 2010-11-25 Spoj indola i njegova farmaceutska upotreba ME02447B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009268040 2009-11-25
EP10833248.7A EP2505586B1 (en) 2009-11-25 2010-11-25 Indole compound and pharmaceutical use thereof
PCT/JP2010/070988 WO2011065402A1 (ja) 2009-11-25 2010-11-25 インドール化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
ME02447B true ME02447B (me) 2016-09-20

Family

ID=44066507

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-107A ME02447B (me) 2009-11-25 2010-11-25 Spoj indola i njegova farmaceutska upotreba

Country Status (31)

Country Link
US (6) US8299070B2 (cg-RX-API-DMAC7.html)
EP (3) EP2505586B1 (cg-RX-API-DMAC7.html)
JP (6) JP5734628B2 (cg-RX-API-DMAC7.html)
KR (1) KR101766502B1 (cg-RX-API-DMAC7.html)
CN (1) CN102712624B (cg-RX-API-DMAC7.html)
AR (1) AR079164A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010323579C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012012529B1 (cg-RX-API-DMAC7.html)
CA (1) CA2781660C (cg-RX-API-DMAC7.html)
CL (1) CL2012001328A1 (cg-RX-API-DMAC7.html)
CO (1) CO6541645A2 (cg-RX-API-DMAC7.html)
CY (1) CY1117559T1 (cg-RX-API-DMAC7.html)
DK (1) DK2505586T3 (cg-RX-API-DMAC7.html)
ES (1) ES2572935T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160579T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028016T2 (cg-RX-API-DMAC7.html)
IL (1) IL220009A (cg-RX-API-DMAC7.html)
ME (1) ME02447B (cg-RX-API-DMAC7.html)
MX (1) MX2012006017A (cg-RX-API-DMAC7.html)
MY (1) MY161095A (cg-RX-API-DMAC7.html)
NZ (1) NZ600840A (cg-RX-API-DMAC7.html)
PE (1) PE20121358A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501021A1 (cg-RX-API-DMAC7.html)
PL (1) PL2505586T3 (cg-RX-API-DMAC7.html)
PT (1) PT2505586E (cg-RX-API-DMAC7.html)
RS (1) RS54910B1 (cg-RX-API-DMAC7.html)
RU (1) RU2556216C2 (cg-RX-API-DMAC7.html)
SI (1) SI2505586T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600258B (cg-RX-API-DMAC7.html)
TW (1) TWI491591B (cg-RX-API-DMAC7.html)
WO (1) WO2011065402A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103800337A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804351A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804302A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼcガンマ2及び耐性に関連した変異
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
ES2748324T3 (es) * 2014-07-04 2020-03-16 Japan Tobacco Inc Método para producir un compuesto de indol
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN104356086A (zh) * 2014-11-28 2015-02-18 湖南科技大学 一种适于工业生产3-吗啉酮的制备方法
CN112118843B (zh) * 2018-05-25 2023-09-29 日本烟草产业株式会社 使用吲哚化合物治疗疼痛或间质性膀胱炎的方法
JP7322007B2 (ja) * 2018-05-25 2023-08-07 日本たばこ産業株式会社 インドール化合物を含むネフローゼ症候群の治療又は予防剤
JP7407705B2 (ja) * 2018-05-25 2024-01-04 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
IL293831B2 (en) 2019-12-20 2024-02-01 Pfizer Benzimidazole derivatives
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
US20240132477A1 (en) * 2020-12-15 2024-04-25 Pfizer Inc. Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease
US20240124439A1 (en) * 2020-12-15 2024-04-18 Pfizer Inc. Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease
US20240279202A1 (en) * 2021-05-03 2024-08-22 Nurix Therapeutics, Inc. Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use
CA3217892A1 (en) * 2021-05-03 2022-11-10 Joel Mcintosh Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
AU2022370351A1 (en) * 2021-10-19 2024-05-02 Nurix Therapeutics, Inc. Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
KR20250166329A (ko) * 2023-04-13 2025-11-27 다나틀라스 파마슈티컬즈 씨오., 엘티디. 티아디아졸론 유도체 및 이의 조성물과 응용

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US953411A (en) * 1908-09-02 1910-03-29 Erastus De Moulin Trick weight-lifting machine.
BR0213562A (pt) * 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
DK1474425T3 (da) * 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2005026175A1 (en) * 2003-09-08 2005-03-24 Aventis Pharmaceuticals Inc. Thienopyrazoles
EP1880993A4 (en) * 2005-04-19 2009-12-30 Kyowa Hakko Kirin Co Ltd NITROGENIC HETEROCYCLIC COMPOUND
EP1968580A2 (en) 2005-12-20 2008-09-17 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
GB0602178D0 (en) * 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
MX2008012482A (es) * 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
AU2007254179B2 (en) * 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2009268040A (ja) 2008-04-23 2009-11-12 Teruhiko Daiho ループアンテナ装置
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
CA2781660C (en) 2018-06-26
PE20121358A1 (es) 2012-10-23
US20130116240A1 (en) 2013-05-09
ES2572935T3 (es) 2016-06-03
JP2021091718A (ja) 2021-06-17
CN102712624A (zh) 2012-10-03
IL220009A0 (en) 2012-07-31
CO6541645A2 (es) 2012-10-16
NZ600840A (en) 2014-01-31
HUE028016T2 (en) 2016-11-28
SMT201600258B (it) 2016-08-31
TW201124378A (en) 2011-07-16
JP2015172051A (ja) 2015-10-01
CY1117559T1 (el) 2017-04-26
AR079164A1 (es) 2011-12-28
US20180362506A1 (en) 2018-12-20
JP5734628B2 (ja) 2015-06-17
AU2010323579C1 (en) 2016-11-03
DK2505586T3 (en) 2016-05-30
PH12012501021A1 (en) 2013-01-14
CA2781660A1 (en) 2011-06-03
JP2017039761A (ja) 2017-02-23
KR101766502B1 (ko) 2017-08-08
EP3059234A1 (en) 2016-08-24
CL2012001328A1 (es) 2012-10-05
BR112012012529B1 (pt) 2021-10-26
RS54910B1 (sr) 2016-10-31
EP3766877A1 (en) 2021-01-20
MY161095A (en) 2017-04-14
RU2556216C2 (ru) 2015-07-10
KR20120096540A (ko) 2012-08-30
MX2012006017A (es) 2012-06-25
JP2011132222A (ja) 2011-07-07
AU2010323579A1 (en) 2012-07-19
PT2505586E (pt) 2016-06-03
BR112012012529A2 (pt) 2016-05-03
EP2505586A4 (en) 2013-05-15
JP2018158935A (ja) 2018-10-11
PL2505586T3 (pl) 2016-12-30
EP2505586A1 (en) 2012-10-03
TWI491591B (zh) 2015-07-11
US20170267662A1 (en) 2017-09-21
US20110306599A1 (en) 2011-12-15
AU2010323579B2 (en) 2016-05-19
HRP20160579T1 (hr) 2016-07-29
EP2505586B1 (en) 2016-03-02
SI2505586T1 (sl) 2016-08-31
CN102712624B (zh) 2014-06-04
US8299070B2 (en) 2012-10-30
US20210284627A1 (en) 2021-09-16
HK1174025A1 (en) 2013-05-31
WO2011065402A1 (ja) 2011-06-03
RU2012126129A (ru) 2013-12-27
JP2020079276A (ja) 2020-05-28
US20200255408A1 (en) 2020-08-13
IL220009A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
ME02447B (me) Spoj indola i njegova farmaceutska upotreba
JP2011132222A5 (cg-RX-API-DMAC7.html)
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
NZ626068A (en) Multicyclic compounds and methods of use thereof
MX2017002241A (es) Compuestos de aminopirimidina como inhibidores de jak.
AR086019A1 (es) COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS
ME02325B (me) Benzoeve kiseline (1-fenil-2-piridin-4-il)-etil estri kao inhibitori fosfodiesteraze
AR061923A1 (es) Compuestos derivados de benzofuran-piperidina
AR081587A1 (es) DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE)
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
ES2618003T3 (es) Compuestos tricíclicos sustituidos como inhibidores de FGFR
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
ECSP066760A (es) Derivado de 4-oxopirimidina de anillos condensados
PE20200388A1 (es) Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock
AR068057A1 (es) Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
MY169179A (en) Novel piperidine compound or salt thereof
AR091781A1 (es) Antagonistas del receptor de 5-ht3
PE20191784A1 (es) Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos
AR059018A1 (es) Derivados de 6- fenil -1h- imidazo (4,5-c) piridina -4- carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina s y/o catepsina k
PH12017501655B1 (en) Morphinan derivative
CO6321159A2 (es) Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias